Covid-19 vaccine development by AstraZeneca - Angel Broking

Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

"AstraZeneca Covid 19 vaccine trials resumes - A vaccine in development by the British-Swedish company AstraZeneca and the University of Oxford a frontrunner in the race for a covid-19 vaccine. Vaccine is in phase 3 trials and Halted global trails 5 days ago, now the global trials resumes of the vaccine. The global trials were halted because one volunteer showed some illness but now indicated that the issue was particularly to the patient and not because of the vaccine. This is positive news for AstraZeneca and global markets."

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.4300.65 as compared to the previous close of Rs. 4025.15. The total number of shares traded during the day was 18993 in over 3569 trades.

The stock hit an intraday high of Rs. 4546.55 and intraday low of 4251.1. The net turnover during the day was Rs. 83040845.

Source : Equity Bulls

Keywords